The HCV protease inhibitor faldaprevir plus pegylated interferon and ribavirin improved 4-week sustained response rates for HIV positive people coinfected with genotype 1 hepatitis C in the STARTVerso4 trial, according to a poster presented at the 64th AASLD Liver Meeting last week in Washington, DC.
http://www.hivandhepatitis.com/hiv-hep-coinfection/hiv-hcv-coinfection/4408-aasld-2013-faldaprevir-pegylated-interferonribavirin-leads-to-early-sustained-response-for-hivhcv-coinfected-patients
http://www.hivandhepatitis.com/hiv-hep-coinfection/hiv-hcv-coinfection/4408-aasld-2013-faldaprevir-pegylated-interferonribavirin-leads-to-early-sustained-response-for-hivhcv-coinfected-patients
No comments:
Post a Comment